OTCMKTS:USRM U.S. Stem Cell (USRM) Stock Price, News & Analysis → AI to Meet the Same Fate as EVs? (From Porter & Company) (Ad) Free USRM Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket Capitalization$70,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsStock AnalysisChartFinancialsHeadlinesSEC Filings Get U.S. Stem Cell alerts: Email Address Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. About U.S. Stem Cell Stock (OTCMKTS:USRM)U.S. Stem Cell, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its pipeline products include MyoCell SDF-1, an autologous muscle-derived cellular therapy for enhancing cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company also offers various courses for physicians and other health care professionals. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.Read More Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. USRM Stock News HeadlinesMarch 28, 2024 | msn.comAutofluorescence Reveals Clues to Stem Cell DormancyMarch 22, 2024 | msn.comStudy finds outcomes after stem cell transplant in elderly patients with AML have improved since 2000March 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… March 19, 2024 | msn.comExamining inflammatory bowel disease after a stem cell transplantMarch 8, 2024 | msn.comLifelike lab-grown skin developed from human stem cellsMarch 8, 2024 | msn.comResearchers develop shortcut to generate brain stem cells for age-related disease researchMarch 8, 2024 | msn.comUnlocking the Healing Potential of Vitamin A in Stem Cell Biology and Wound RepairMarch 7, 2024 | msn.comVitamin A may play a central role in stem cell biology and wound repairMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… March 6, 2024 | msn.comExploring the inner workings of stem cells: When location changes the messageMarch 6, 2024 | msn.comCompany Trying to Resurrect a Mammoth Makes a Stem Cell BreakthroughMarch 2, 2024 | msn.comStem Cell Transplant cures California man of HIV & Acute LeukemiaFebruary 28, 2024 | msn.comNHS ‘fast tracks’ new therapy for stem cell patientsFebruary 26, 2024 | msn.comMan 'cured' of HIV and leukaemia after receiving stem cells from donor with rare mutationFebruary 26, 2024 | msn.comRevolutionary stem cell culture method produces full model of human central nervous systemFebruary 26, 2024 | msn.comScientists devise novel strategy to seek and destroy leukemia stem cellsFebruary 26, 2024 | msn.comHuman stem cells coaxed to mimic the very early central nervous systemFebruary 26, 2024 | msn.comScientists make a brand new strategy to eradicate leukemia stem cellsFebruary 22, 2024 | msn.comStem cells 'migrate' to repair damaged lung cells, study showsFebruary 21, 2024 | yahoo.com'Heartbeat of The Heart of it All': STEM labs at OSU-Mansfield will boost state's economyFebruary 18, 2024 | msn.comAstronauts conduct sensitive research using stem cells to understand how our bones workFebruary 15, 2024 | msn.comWhy leukemic stem cells not harmed by chemotherapy begin to grow and produce AML cells after treatmentFebruary 15, 2024 | msn.comThese lab-grown hearts made from human stem cells are used to train AI to detect heart diseasesFebruary 7, 2024 | msn.comHow your stem cells could save a lifeJanuary 30, 2024 | msn.comU.S. researchers using stem cells from blood to treat cancer.January 29, 2024 | news.yahoo.comThe untapped potential of stem cells in menstrual bloodJanuary 29, 2024 | msn.comISU stem-cell research aims to end bone-marrow transplantsSee More Headlines Receive USRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for U.S. Stem Cell and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2019Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Commercial physical research Sub-IndustryN/A Current SymbolOTCMKTS:USRM Previous SymbolNASDAQ:BHRT CUSIPN/A CIK1388319 Webwww.us-stemcell.com Phone(954) 835-1500Fax954-845-9976Employees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$80,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / BookN/AMiscellaneous Outstanding Shares661,510,000Free Float550,903,000Market Cap$70,000.00 OptionableNot Optionable Beta-1.38 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Michael Tomas (Age 58)CEO, President, CFO & Director Dr. Colleen RobbSenior Compliance OfficerMr. Phil PosaSenior Vice President of U.S. & International SalesMs. Evelyn FloresCorporate ControllerDr. Sergio PinskiMedical Director & Member of Scientific Advisory BoardKey CompetitorsAffinity Energy and HealthOTCMKTS:ALGXYDeltagenOTCMKTS:DGENDNAPrint GenomicsOTCMKTS:DNAGProtalexOTCMKTS:PRTXRedpoint BioOTCMKTS:RPBCView All Competitors USRM Stock Analysis - Frequently Asked Questions How were U.S. Stem Cell's earnings last quarter? U.S. Stem Cell, Inc. (OTCMKTS:USRM) posted its quarterly earnings data on Wednesday, August, 7th. The company reported $0.00 earnings per share for the quarter. The business earned $1.30 million during the quarter. What other stocks do shareholders of U.S. Stem Cell own? Based on aggregate information from My MarketBeat watchlists, some companies that other U.S. Stem Cell investors own include Orion Energy Systems (OESX), Actinium Pharmaceuticals (ATNM), Cleveland BioLabs (CBLI), Digi International (DGII), SeaChange International (SEAC), SMTC (SMTX), Axsome Therapeutics (AXSM) and How do I buy shares of U.S. Stem Cell? Shares of USRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:USRM) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding U.S. Stem Cell, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.